Immune-cell expansion accompanied tumor shrinkage in four anal cancer patients

Oncolytics Biotech reported that pelareorep increased HPV-specific immune responses in anal cancer patients. Seven of eight patients showed significant biomarker increases after one cycle, and all four evaluable patients had tumor shrinkage after three cycles. The study showed improved response rates and duration compared to current therapies. The Phase 1/2 study combines pelareorep with a checkpoint inhibitor.

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers Pelareorep-driven changes in the tumor microenvironment are associated with tumor responses and shrinkage Immune activation levels

Oncolytics Biotech (ONCY) reported that pelareorep increased HPV-16-specific T-cell and tumor-infiltrating lymphocyte clones in a study of anal cancer patients. The company also noted efficacy signals compared to current therapies, but did not provide specific response rates.

Oncolytics Biotech reported updated data from the GOBLET trial showing durable responses and extended survival in patients with squamous cell anal cancer (SCAC) treated with pelareorep and atezolizumab. The median duration of response was approximately 15 months, and all responding patients survived beyond 12 months. The company plans to pursue registration in SCAC and explore additional studies in other HPV-associated cancers.

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Oncolytics Biotech ® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers GOBLET Cohort 4 demonstrates approximately 15-month median duration of response that exceeds historical results fo

Oncolytics Biotech (NASDAQ:ONCY) reported updated data from its Phase 1/2 GOBLET study, showing a 15-month median response duration for pelareorep combined with atezolizumab in anal cancer patients, compared to 9.5 months for FDA-approved retifanlimab. The company plans further studies and potential expansion into HPV-associated head and neck cancer.